Zhejiang Hisun Pharmaceutical Co Ltd (Hisun) manufactures and commercializes drugs to treat tumors, infections, cardiovascular, endocrine, depression and orthopedic disorders. The company’s product portfolio includes anti-tumor and anti-viral, hypoglycemic drugs, anti-infection drugs animal health products, anthelmintic, oral solid preparation drugs, weight loss pills, calcium supplements, immune suppressants and biological medicines, among others. It provides medical information, product consultation and adverse drug reaction reports. Hisun operates research and development facilities in Shanghai and Beijing, China. The company distributes its products in domestic markets and overseas markets. Hisun is headquartered in Taizhou, Zhejiang, China.
Headquarters
China
Address
No. 46, Waisha Road, Jiaojiang District, Taizhou, Zhejiang, 318000
Website
www.hisunpharm.com
Telephone
86 571 85278141
No of Employees
8,325
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
600267 (SHA)
Revenue (2021)
$1.8B
-0.8%
(2021 vs 2020)
EPS
XYZ
Net Income (2021)
XYZ
0.4%
(2021 vs 2020)
Market Cap*
$1.3B
Net Profit Margin (2021)
XYZ
1.3%
(2021 vs 2020)
* As of and is in US$
Zhejiang Hisun Pharmaceutical Co Ltd premium industry data and analytics
Products and Services
| Products |
|---|
| Active Pharmaceutical Ingredients |
| Anti-Tumor Drugs |
| Cardiovascular Drugs |
| XYZ |
| XYZ |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2023 | Contracts/Agreements | In April, the company and Nanjing Normal University signed a strategic cooperation framework agreement to cooperate in the research and development of synthetic biology technology and the cultivation and exchange of high-level talents. |
| 2022 | New Products/Services | In May, the company launched insulin product, Insulin Aspart Injection (Hisaining). |
| 2022 | Contracts/Agreements | In May, Hisun Pharmaceutical and Zhejiang Shengzhao Pharmaceutical Technology Co., Ltd. signed the strategic cooperation framework agreement for the promotion and equity investment. |
Competitor Comparison
| Key Parameters | Zhejiang Hisun Pharmaceutical Co Ltd | Shanghai Fosun Pharmaceutical (Group) Co Ltd | Jiangsu Hengrui Medicine Co Ltd | Tasly Pharmaceutical Group Co Ltd | Kangmei Pharmaceutical Co Ltd |
|---|---|---|---|---|---|
| Headquarters | China | China | China | China | China |
| City | Taizhou | Shanghai | Lianyungang | Tianjin | Shenzhen |
| State/Province | Zhejiang | Shanghai | Jiangsu | Tianjin | Guangdong |
| No. of Employees | 8,325 | 40,370 | 20,636 | 9,183 | 6,371 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Jiang Guoping | Chairman | Executive Board | 2018 | 62 |
| Chen Xiaohua | Senior Vice President; Vice Chairman | Executive Board | 2017 | 59 |
| Du Jiaqiu | Senior Vice President; Director | Executive Board | 2019 | 49 |
| Zhang Zhenying | Director - Financial | Senior Management | 2019 | 39 |
| Jin Hongshun | Senior Vice President | Senior Management | 2019 | 47 |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward